Published in Aliment Pharmacol Ther on June 03, 2013
Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology (2015) 3.45
Letter: East-West differences in the economic impact of functional dyspepsia. Aliment Pharmacol Ther (2013) 1.06
Functional dyspepsia: new insights into pathogenesis and therapy. Korean J Intern Med (2016) 0.92
Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease. Dig Dis Sci (2016) 0.77
Correlation between social factors and anxiety-depression in function dyspepsia: do relationships exist? Prz Gastroenterol (2014) 0.77
Comparing the Areas of Interest in the Field of Functional Gastrointestinal Disorder and Neurogastroenterology and Motility Between the East and the West. J Neurogastroenterol Motil (2015) 0.76
The Initial Management and Endoscopic Outcomes of Dyspepsia in a Low-Risk Patient Population. Dig Dis Sci (2016) 0.76
Functional Dyspepsia: Advances in Diagnosis and Therapy. Gut Liver (2017) 0.75
Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia. World J Gastrointest Pharmacol Ther (2017) 0.75
The Utility of Endoscopic Biopsies in Patients with Normal Upper Endoscopy. Can J Gastroenterol Hepatol (2016) 0.75
Effects and mechanisms of auricular electroacupuncture on gastric hypersensitivity in a rodent model of functional dyspepsia. PLoS One (2017) 0.75
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. Sci Rep (2015) 0.75
Validation of the Kinyarwanda-version Short-Form Leeds Dyspepsia Questionnaire and Short-Form Nepean Dyspepsia Index to assess dyspepsia prevalence and quality-of-life impact in Rwanda. BMJ Open (2016) 0.75
Effect of Chinese patent medicine Si-Mo-Tang oral liquid for functional dyspepsia: A systematic review and meta-analysis of randomized controlled trials. PLoS One (2017) 0.75
Letter: East-West differences in the economic impact of functional dyspepsia--authors' reply. Aliment Pharmacol Ther (2013) 0.75
Medication risk-taking behavior in functional dyspepsia patients. Clin Transl Gastroenterol (2015) 0.75
Weikangning therapy in functional dyspepsia and the protective role of Nrf2. Exp Ther Med (2017) 0.75
Cerebral mechanism of puncturing at He-Mu point combination for functional dyspepsia: study protocol for a randomized controlled parallel trial. Neural Regen Res (2017) 0.75
Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool. Dig Dis Sci (2015) 0.75
Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA (1998) 4.62
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut (2008) 3.92
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut (2008) 3.81
Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med (2001) 3.68
A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14
Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol (1999) 3.01
Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology (1996) 3.00
The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut (2012) 2.96
Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol (2000) 2.89
Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut (2008) 2.82
Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med (1995) 2.78
Risk factors associated with symptoms of gastroesophageal reflux. Am J Med (1999) 2.75
The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther (2013) 2.73
Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol (1996) 2.73
The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med (1995) 2.73
Review article: Associations between Helicobacter pylori and obesity--an ecological study. Aliment Pharmacol Ther (2014) 2.69
Prevalence of Helicobacter pylori in specific forms of gastritis. Further evidence supporting a pathogenic role for H. pylori in chronic nonspecific gastritis. Dig Dis Sci (1991) 2.67
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. Aliment Pharmacol Ther (2014) 2.67
Menetrier's disease: a form of hypertrophic gastropathy or gastritis? Gastroenterology (1993) 2.52
Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol (1998) 2.38
Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther (2004) 2.35
Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology (1990) 2.32
Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol Ther (2014) 2.30
Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther (2003) 2.28
A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol (2000) 2.27
Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl (1998) 2.26
Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol (2001) 2.23
Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology (2001) 2.22
Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: a population-based study. Aliment Pharmacol Ther (2015) 2.17
Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut (1992) 2.15
Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol (2001) 2.12
The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. Aliment Pharmacol Ther (2014) 2.05
The association between non-ulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol (1985) 2.01
Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol (1998) 1.96
Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol (2001) 1.85
Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol (2001) 1.84
Non-cardiac chest pain: prevalence, risk factors, impact and consulting--a population-based study. Aliment Pharmacol Ther (2003) 1.84
Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.81
Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut (2004) 1.76
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res (2004) 1.76
Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut (1997) 1.75
The effects of lottery incentive and length of questionnaire on health survey response rates: a randomized study. J Clin Epidemiol (1999) 1.73
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int (2011) 1.72
Differences in gastric mechanosensory function after repeated ramp distensions in non-consulters with dyspepsia and healthy controls. Gut (2000) 1.70
Association of anxiety, neuroticism, and depression with dyspepsia of unknown cause. A case-control study. Gastroenterology (1986) 1.69
Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther (2011) 1.68
Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther (2003) 1.68
A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther (2014) 1.64
Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc (2000) 1.64
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther (2004) 1.64
Non-cardiac chest pain: squeezing the life out of the Australian healthcare system? Med J Aust (2000) 1.63
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut (2004) 1.60
Eosinophil infiltration and degranulation in normal human tissue. Anat Rec (1998) 1.59
Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology (1995) 1.59
Does Helicobacter pylori colonize the gastric mucosa of Meckel's diverticulum? Mayo Clin Proc (1990) 1.59
Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil (2005) 1.56
ABC of the upper gastrointestingal tract: Indigestion: When is it functional? BMJ (2001) 1.56
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc (1992) 1.53
Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil (2006) 1.51
Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther (2007) 1.51
Visceral perception in functional gastro-intestinal disorders: disease marker or epiphenomenon? Dig Dis (1997) 1.51
Factors associated with consulting medical or non-medical practitioners for dyspepsia: an australian population-based study. Aliment Pharmacol Ther (2000) 1.51
Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study. Aliment Pharmacol Ther (2006) 1.49
Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study. Scand J Gastroenterol (2004) 1.49
Oesophageal eosinophilic infiltration in patients with noncardiac chest pain. Aliment Pharmacol Ther (2011) 1.49
Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. Am J Gastroenterol (1997) 1.48
Management of gastro-oesophageal reflux disease in general practice. BMJ (2001) 1.48
Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc (1992) 1.46
Abuse and functional gastrointestinal disorders: what is the link and should we care? Gastroenterology (1996) 1.46
Dysphagia: epidemiology, risk factors and impact on quality of life--a population-based study. Aliment Pharmacol Ther (2008) 1.46
Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis (2009) 1.45
Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther (2012) 1.45
Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol (2001) 1.43
Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci (1995) 1.41
Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol (2000) 1.39
Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology (1990) 1.39
Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol (1996) 1.38
Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol (2001) 1.37
Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J (2000) 1.34
Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther (2004) 1.33
Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol (1998) 1.33
Familial aggregation of irritable bowel syndrome: a prospective study. Gut (2003) 1.33
Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther (2007) 1.32
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther (2005) 1.32
The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol (2000) 1.32
Patient characteristics, clinical, endoscopic, and histologic findings in adult eosinophilic esophagitis: a case series and systematic review of the medical literature. Dis Esophagus (2007) 1.32
Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther (2003) 1.31
Validation of the Mayo Dysphagia Questionnaire. Dis Esophagus (2007) 1.29
Modeling and reinforcement of the sick role during childhood predicts adult illness behavior. Psychosom Med (1995) 1.29
Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology (1990) 1.29
Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther (2009) 1.28
Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther (2011) 1.27
Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther (2004) 1.27
Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol (2011) 1.26
Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med (1999) 1.26
Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc (1998) 1.24